GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Return-on-Tangible-Asset

Rosetta Genomics (Rosetta Genomics) Return-on-Tangible-Asset : -91.19% (As of Jun. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Rosetta Genomics's annualized Net Income for the quarter that ended in Jun. 2017 was $-8.28 Mil. Rosetta Genomics's average total tangible assets for the quarter that ended in Jun. 2017 was $9.08 Mil. Therefore, Rosetta Genomics's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2017 was -91.19%.

The historical rank and industry rank for Rosetta Genomics's Return-on-Tangible-Asset or its related term are showing as below:

ROSGQ's Return-on-Tangible-Asset is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -9.45
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Rosetta Genomics Return-on-Tangible-Asset Historical Data

The historical data trend for Rosetta Genomics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Return-on-Tangible-Asset Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -60.49 -44.16 -67.32 -87.38 -94.42

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.48 -77.43 -111.63 -157.38 -91.19

Competitive Comparison of Rosetta Genomics's Return-on-Tangible-Asset

For the Diagnostics & Research subindustry, Rosetta Genomics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rosetta Genomics's Return-on-Tangible-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rosetta Genomics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Rosetta Genomics's Return-on-Tangible-Asset falls into.



Rosetta Genomics Return-on-Tangible-Asset Calculation

Rosetta Genomics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2016 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2016 )  (A: Dec. 2015 )(A: Dec. 2016 )
=-16.233/( (22.423+11.961)/ 2 )
=-16.233/17.192
=-94.42 %

Rosetta Genomics's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2017 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2017 )  (Q: Dec. 2016 )(Q: Jun. 2017 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2017 )  (Q: Dec. 2016 )(Q: Jun. 2017 )
=-8.284/( (11.961+6.207)/ 2 )
=-8.284/9.084
=-91.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2017) net income data.


Rosetta Genomics  (OTCPK:ROSGQ) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Rosetta Genomics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (Rosetta Genomics) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458